Compare AU
Compare SNAS vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are SNAS and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
SNAS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 21 | 63 |
Median incremental investment | $1,850.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,345.79 | $1,921.92 |
Average age group | > 35 | 26 - 35 |
Key Summary
SNAS | DRUG | |
|---|---|---|
Strategy | SNAS.AX was created on 2020-07-13 by ETFS. The fund's investment portfolio concentrates primarily on multi-strategy alternatives. The investment objective of the Fund is to provide investors with geared returns (before fees and expenses), that are inversely related with the performance of the Nasdaq 100 Index (the Index). | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Nasdaq 100 Short Hedge Fund (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 1 % | 0.57 % |
Key Summary
SNAS | DRUG | |
|---|---|---|
Issuer | ETFS | BetaShares |
Tracking index | NASDAQ 100 Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 1 % | 0.57 % |
Price | $22.88 | $8.25 |
Size | $41.360 million | $182.401 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | - % | 1.90 % |
Market | ASX | ASX |
First listed date | 12/07/2020 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
SNAS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 21 | 63 |
Median incremental investment | $1,850.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,345.79 | $1,921.92 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
SNAS | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
SNAS | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |